Atazanavir
- Generic Name
- Atazanavir
- Brand Names
- Evotaz, Reyataz, Atazanavir Krka, Atazanavir Viatris (previously Atazanavir Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C38H52N6O7
- CAS Number
- 198904-31-3
- Unique Ingredient Identifier
- QZU4H47A3S
- Background
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.
- Indication
Atazanavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older weighing at least 5kg. Atazanavir is also indicated in combination with cobicistat and other antiretrovirals for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35kg.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
- Conditions
- HIV InfectionsLipodystrophy
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2007-11-01
- Lead Sponsor
- Clinical Alliance for Research & Education - Infectious Diseases, LLC.
- Registration Number
- NCT00426296
- Locations
- 🇺🇸
Whitman-Walker Clinic, Washington, District of Columbia, United States
Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2009-02-06
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 19
- Registration Number
- NCT00420355
- Locations
- 🇺🇸
OUHSC General Clinical Research Center, Oklahoma City, Oklahoma, United States
Pharmacokinetic Study of 2 Doses of ATV/r OD + 2 NRTIs in Thai HIV-1 Infected Patients
- First Posted Date
- 2006-12-15
- Last Posted Date
- 2020-07-17
- Target Recruit Count
- 22
- Registration Number
- NCT00411957
- Locations
- 🇹🇭
HIV-NAT, Thai Red Cross AIDS Research Center, Bangkok, Thailand
Bioequivalence Study of Atazanavir 300 mg Capsule
- First Posted Date
- 2006-10-27
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT00393328
- Locations
- 🇺🇸
Local Institution, Hamilton, New Jersey, United States
Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2006-10-18
- Last Posted Date
- 2014-01-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 576
- Registration Number
- NCT00389207
- Locations
- 🇲🇽
1100.1470.55001 Boehringer Ingelheim Investigational Site, Col. Toriello Guerra, Mexico
🇵🇹1100.1470.35103 Boehringer Ingelheim Investigational Site, Porto, Portugal
🇨🇭1100.1470.41002 Boehringer Ingelheim Investigational Site, Zürich, Switzerland
Drug Interaction Study With Atazanavir Administered With and Without Ritonavir and a Cytochrome P450 Substrate Rosiglitazone
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 14
- Registration Number
- NCT00362726
- Locations
- 🇺🇸
Local Institution, Hamilton, New Jersey, United States
Drug Interaction Study With Proton Pump Inhibitor
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 56
- Registration Number
- NCT00357240
- Locations
- 🇺🇸
Local Institution, Hamilton, New Jersey, United States
Dose Finding Confirmation of Atazanavir With Ritonavir and Efavirenz (ATV/RTV + EFV) in Healthy Subjects
- Conditions
- HIV InfectionsProtease Inhibitor
- Interventions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2011-04-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT00357188
- Locations
- 🇺🇸
Local Institution, Hamilton, New Jersey, United States
Atazanavir Twice Daily
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2011-04-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 18
- Registration Number
- NCT00357721
- Locations
- 🇺🇸
Local Institution, Hamilton, New Jersey, United States
Study to Evaluate the Influence of Nevirapine to Atazanavir in Steady State Equilibrium in HIV Patients
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2006-07-25
- Last Posted Date
- 2019-12-04
- Lead Sponsor
- Germans Trias i Pujol Hospital
- Target Recruit Count
- 14
- Registration Number
- NCT00355719
- Locations
- 🇪🇸
Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital Sant Jaume de Calella, Calella, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.